The article discusses a study on the effects of in utero aspirin exposure during the second trimester on child neurocognitive development. While the study found a potential association between aspirin use and enhanced neurodevelopment, it acknowledges limitations such as the lack of detailed data on aspirin dosage and duration. The authors caution against assuming causation over correlation and highlight the need for further research to understand the potential benefits and risks of in utero aspirin exposure. It is suggested that rigorous prospective studies are necessary to provide more conclusive evidence on the effects of low-dose aspirin on neurocognitive development.